PA8846901A1 - Inhibidores de cinasa akt y p70 s6. - Google Patents
Inhibidores de cinasa akt y p70 s6.Info
- Publication number
- PA8846901A1 PA8846901A1 PA20098846901A PA8846901A PA8846901A1 PA 8846901 A1 PA8846901 A1 PA 8846901A1 PA 20098846901 A PA20098846901 A PA 20098846901A PA 8846901 A PA8846901 A PA 8846901A PA 8846901 A1 PA8846901 A1 PA 8846901A1
- Authority
- PA
- Panama
- Prior art keywords
- formula
- akt
- inhibitors
- cinase
- present
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract 1
- 235000011613 Pinus brutia Nutrition 0.000 abstract 1
- 241000018646 Pinus brutia Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003197 protein kinase B inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11327308P | 2008-11-11 | 2008-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8846901A1 true PA8846901A1 (es) | 2010-06-28 |
Family
ID=41402451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20098846901A PA8846901A1 (es) | 2008-11-11 | 2009-10-29 | Inhibidores de cinasa akt y p70 s6. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8148387B2 (OSRAM) |
| EP (1) | EP2358710B1 (OSRAM) |
| JP (1) | JP5432275B2 (OSRAM) |
| KR (1) | KR101334460B1 (OSRAM) |
| CN (1) | CN102216302B (OSRAM) |
| AR (1) | AR074072A1 (OSRAM) |
| AU (1) | AU2009314324B2 (OSRAM) |
| BR (1) | BRPI0921916A2 (OSRAM) |
| CA (1) | CA2743019C (OSRAM) |
| CO (1) | CO6382114A2 (OSRAM) |
| CR (1) | CR20110240A (OSRAM) |
| CY (1) | CY1113409T1 (OSRAM) |
| DK (1) | DK2358710T3 (OSRAM) |
| DO (1) | DOP2011000129A (OSRAM) |
| EA (1) | EA018947B1 (OSRAM) |
| EC (1) | ECSP11011048A (OSRAM) |
| ES (1) | ES2391704T3 (OSRAM) |
| HN (1) | HN2011001247A (OSRAM) |
| HR (1) | HRP20120738T1 (OSRAM) |
| IL (1) | IL211940A (OSRAM) |
| JO (1) | JO2822B1 (OSRAM) |
| MA (1) | MA32776B1 (OSRAM) |
| MX (1) | MX2011005000A (OSRAM) |
| MY (1) | MY161461A (OSRAM) |
| NZ (1) | NZ592062A (OSRAM) |
| PA (1) | PA8846901A1 (OSRAM) |
| PE (1) | PE20110807A1 (OSRAM) |
| PL (1) | PL2358710T3 (OSRAM) |
| PT (1) | PT2358710E (OSRAM) |
| RS (1) | RS52520B (OSRAM) |
| SI (1) | SI2358710T1 (OSRAM) |
| TN (1) | TN2011000207A1 (OSRAM) |
| TW (1) | TWI422587B (OSRAM) |
| UA (1) | UA100190C2 (OSRAM) |
| WO (1) | WO2010056563A1 (OSRAM) |
| ZA (1) | ZA201102549B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120106714A (ko) | 2009-07-02 | 2012-09-26 | 사노피 | 신규 (6-옥소-1,6-디히드로-피리미딘-2-일)아미드 유도체, 그의 제조법, 및 ａｋｔ(ｐｋｂ) 인산화 억제제로서의 그의 제약 용도 |
| MX2012004780A (es) * | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
| HUE026323T2 (en) | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as akt kinase inhibitors |
| US8927572B2 (en) * | 2011-07-09 | 2015-01-06 | Xuanzhu Pharma Co., Ltd. | Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof |
| WO2013040059A1 (en) | 2011-09-12 | 2013-03-21 | Merck Patent Gmbh | Novel imidazole amines as modulators of kinase activity |
| WO2013040044A1 (en) | 2011-09-12 | 2013-03-21 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| AR093512A1 (es) | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados heterociclicos como moduladores de la actividad de cinasas |
| WO2014078634A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
| WO2014143612A1 (en) * | 2013-03-11 | 2014-09-18 | Merck Patent Gmbh | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
| MX2016010268A (es) * | 2014-02-11 | 2016-10-13 | Merck Patent Gmbh | Pirimidinimidazolaminas como modulares de actividad de cinasa. |
| TW201718574A (zh) | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| WO2017200087A1 (ja) * | 2016-05-20 | 2017-11-23 | 大鵬薬品工業株式会社 | 新規５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン誘導体 |
| MX2022011188A (es) | 2020-03-17 | 2022-11-08 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo. |
| CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| JP2024535857A (ja) | 2021-09-17 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法 |
| JPWO2024009977A1 (OSRAM) * | 2022-07-05 | 2024-01-11 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| WO2006071819A1 (en) | 2004-12-28 | 2006-07-06 | Exelixis, Inc. | [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| FI3719018T3 (fi) | 2006-04-25 | 2025-10-07 | Astex Therapeutics Ltd | Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2009
- 2009-10-28 AR ARP090104158A patent/AR074072A1/es unknown
- 2009-10-29 TW TW098136731A patent/TWI422587B/zh not_active IP Right Cessation
- 2009-10-29 JO JO2009400A patent/JO2822B1/en active
- 2009-10-29 PA PA20098846901A patent/PA8846901A1/es unknown
- 2009-11-03 EA EA201170680A patent/EA018947B1/ru not_active IP Right Cessation
- 2009-11-03 UA UAA201105367A patent/UA100190C2/ru unknown
- 2009-11-03 BR BRPI0921916A patent/BRPI0921916A2/pt not_active IP Right Cessation
- 2009-11-03 JP JP2011536383A patent/JP5432275B2/ja active Active
- 2009-11-03 NZ NZ592062A patent/NZ592062A/xx not_active IP Right Cessation
- 2009-11-03 CA CA2743019A patent/CA2743019C/en not_active Expired - Fee Related
- 2009-11-03 SI SI200930348T patent/SI2358710T1/sl unknown
- 2009-11-03 PT PT09744896T patent/PT2358710E/pt unknown
- 2009-11-03 PL PL09744896T patent/PL2358710T3/pl unknown
- 2009-11-03 MY MYPI2011002030A patent/MY161461A/en unknown
- 2009-11-03 HR HRP20120738AT patent/HRP20120738T1/hr unknown
- 2009-11-03 US US12/611,139 patent/US8148387B2/en active Active
- 2009-11-03 KR KR1020117010569A patent/KR101334460B1/ko not_active Expired - Fee Related
- 2009-11-03 ES ES09744896T patent/ES2391704T3/es active Active
- 2009-11-03 AU AU2009314324A patent/AU2009314324B2/en not_active Ceased
- 2009-11-03 DK DK09744896.3T patent/DK2358710T3/da active
- 2009-11-03 RS RS20120443A patent/RS52520B/sr unknown
- 2009-11-03 WO PCT/US2009/063020 patent/WO2010056563A1/en not_active Ceased
- 2009-11-03 EP EP09744896A patent/EP2358710B1/en active Active
- 2009-11-03 CN CN2009801449532A patent/CN102216302B/zh active Active
- 2009-11-03 PE PE2011001018A patent/PE20110807A1/es not_active Application Discontinuation
- 2009-11-03 MX MX2011005000A patent/MX2011005000A/es active IP Right Grant
-
2011
- 2011-03-24 IL IL211940A patent/IL211940A/en not_active IP Right Cessation
- 2011-04-06 ZA ZA2011/02549A patent/ZA201102549B/en unknown
- 2011-04-25 TN TN2011000207A patent/TN2011000207A1/fr unknown
- 2011-05-03 HN HN2011001247A patent/HN2011001247A/es unknown
- 2011-05-06 CR CR20110240A patent/CR20110240A/es unknown
- 2011-05-09 MA MA33822A patent/MA32776B1/fr unknown
- 2011-05-09 DO DO2011000129A patent/DOP2011000129A/es unknown
- 2011-05-11 EC EC2011011048A patent/ECSP11011048A/es unknown
- 2011-05-12 CO CO11058555A patent/CO6382114A2/es active IP Right Grant
-
2012
- 2012-10-05 CY CY20121100928T patent/CY1113409T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8846901A1 (es) | Inhibidores de cinasa akt y p70 s6. | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| BR112012011328A2 (pt) | inibidores de akt | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| EA201101341A1 (ru) | Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе | |
| EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
| UA118177C2 (uk) | Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну | |
| CR20120283A (es) | Inhibidor de bromodominio de benzodiazepina | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| MY153915A (en) | Organic compounds | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| IL195030A (en) | Dpp iv inhibitor formulations | |
| CU23774A3 (es) | Inhibición de arni de expresión de alfa-enac | |
| CU20120002A7 (es) | DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA | |
| MX341849B (es) | Nitrilos espirociclicos como inhibidores de proteasa. | |
| EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| AR074379A1 (es) | Inhibidor de triazolotiadiazola de la proteina quinasa c-met | |
| PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
| CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
| CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. | |
| ECSP088374A (es) | Formulacion de aerosol para inhalacion | |
| CL2012001759A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica. | |
| UY32360A (es) | Compuestos de etanamina y métodos de utilización de los mismos 545 | |
| NI201000139A (es) | ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE |